Age at onset of Huntington disease is not modulated by the R72P variation in TP53 and the R196K variation in the gene coding for the human caspase activated DNase (hCAD)

Larissa Arning*1, Peter H Kraus2, Carsten Saft2, Jürgen Andrich2 and Jörg T Epplen1

Address: 1Department of Human Genetics, Ruhr-University, 44780 Bochum, Germany and 2Department of Neurology, St. Josef-Hospital, Ruhr-University, 44791 Bochum, Germany

Email: Larissa Arning* - larissa.arning@rub.de; Peter H Kraus - peter.h.kraus@rub.de; Carsten Saft - carsten.saft@cityweb.de; Jürgen Andrich - juergen.andrich@rub.de; Jörg T Epplen - joerg.t.epplen@rub.de

* Corresponding author

Abstract

Background: TP53 is an attractive candidate for modifying age of onset (AO) in Huntington disease (HD): The amino-terminus of the mutated huntingtin (htt) exon 1 translation product has functional properties which may affect critically the TP53 pathway in HD neurons. The pathogenic domain of mutant htt interacts with nuclear transcription factors, and it potentially modulates TP53-induced transcriptional events. A single nucleotide polymorphism (SNP) resulting in the R72P exchange in TP53 protein might modulate the variation in AO. In addition, also the R196K replacement in human caspase activated DNase (hCAD) may theoretically affect the AO.

Methods: We have genotyped the polymorphisms R72P and R196K in a well established cohort of 167 unrelated HD patients.

Results: The expanded CAG repeat explained 30.8% of the variance in AO. Adding the genotypes of the SNPs investigated did not affect the variance of the AO variance explained.

Conclusion: In this replication study, no association was found explaining a significant amount of the variability in AO of HD thus contradicting a recent report.

Background

Huntington disease (HD) is an autosomal dominantly transmitted, neurodegenerative disorder characterized by motor abnormalities, cognitive dysfunction and psychiatric symptoms [1]. HD is caused by an expansion of a polyglutamine tract in the amino-terminal portion of the protein huntingtin (htt), which apparently acquires a deleterious gain of function [2]. The length of the polyglutamine tract is the most important factor in determining AO of HD, although substantial variability remains after controlling for repeat length, particularly in cases where CAG repeat numbers range in the high 30s or low 40s [3]. Therefore, defining independent AO modifying factors is of great importance, since they may provide further clues pertaining to the pathology arising from the expanded repeats. In mammals, TP53 is the most important tumor suppressor gene. A variety of intracellular stress signals activate TP53 to induce either transient cell
cycle arrest with stimulation of repair activities, senescence or apoptosis [4]. It has been proposed that the amino-terminal portion of mutant htt encoded by exon 1 exerts functional properties with significant consequences for the TP53 pathway in HD neurons. The pathogenic domain of mutant htt interacts with critical transcription factors and potentially modulates TP53-induced transcriptional events [5]. It has been shown that the two variations of the common codon 72 polymorphism (Arg / Pro) in the TP53 gene differ with respect to the ability to suppress cellular transformation [6] and induce apoptosis [7]. Therefore, the R72P polymorphism represents a good candidate for modulating the AO of HD. Recently this polymorphism was described to explain a significant part of the variance in the AO in HD [8]. In the same study also the SNP R196K was investigated in the human caspase activated DNase protein (hCAD), since DNase is responsible for DNA degradation during apoptosis [9]. Variations in the latter SNP were likewise found to exert an additionally significant impact on the AO of HD. We re-investigated here whether TP53 and hCAD variations modulate the AO of HD in our established cohort.

Methods
Our study population consists of 167 unrelated patients with the clinical diagnosis of HD [10], recruited from the Huntington Center (HZ) NRW, Bochum (Germany). Clinical assessment and determination of the motor AO was performed exclusively by two experienced neurologists/psychiatrists of the HZ NRW. Controls (healthy blood donors from the German population of Essen) were also genotyped for comparison. Informed consent was obtained from all patients and controls. We purposely selected a cohort with limited extent of CAG expansions (41–45), since within this defined range the expansions show linear correlation with AO. Within this range ~75% of all elongated CAG alleles are comprised, and they are distributed normally. CAG repeat sizes were determined after PCR amplification of genomic DNA from peripheral white blood cells. CAG repeats were amplified by established methods [11]. The polymorphism R72P in the TP53 gene was demonstrated after PCR amplification using the following primers: 5’-GAGGACCTGGCTCTCTGACT-3’ and 5’-TCTGGTGAAGTACGTTGCCAT-3’ under the same conditions mentioned above. PCR products were digested with the restriction enzyme Alu I at 37°C overnight. Digested DNA was electrophoresed on 3% agarose gels. The restriction fragments of the G allele were 129, 99 and 13 bp in length. The A allele harbors an additional restriction site so that the 99 bp fragment is digested into 73 and 26 bp. The variability in AO attributable to the CAG repeat number was calculated by linear regression. For the regression analysis, we used the AO as the dependent variable, the respective genotypes as independent variables.

The CAG repeat number was considered as numerical variables, the other putative modifying genotypes were considered as nominal variables. SPSS Ver.11.0 for Windows (SPSS Inc.) was used for all statistical analyses.

Results and discussion
As detailed in an earlier study concerning our clinically thoroughly characterised HD cohort, the expanded CAG repeat explained 30.8% of the variance in AO [10]. Adding the genotypes of the SNPs investigated here did not affect the variance of the AO variance explained (Table 1). Chattopadhyay et al. further conducted a case-control study for these SNPs and found genotype GG in the TP53 gene to be a significant risk factor for HD. In order to retest also this assumption, we performed a case-control study as well. As expected, there was no difference between the case and control groups. All frequencies observed were in Hardy-Weinberg equilibrium and correspond to those reported for the general Caucasian population [12].

Conclusion
Our study failed to replicate the association between the genotypes at the R72P polymorphism in TP53 and R196K polymorphism in hCAD genes with the AO of HD. Since we employed a larger cohort of exceptionally well-characterized HD patients the initial association may have been due to chance or to bias as introduced by population stratification. It is, however, possible that a true association exists in Indians. The effect size may also be quite small, requiring an even larger sample size than ours for Caucasians.

Competing interests
The author(s) declare that they have no competing interests.
Table 1: Genotype frequencies and linear regression analysis of the SNPs in TP53 and hCAD genes

| Gene | Genotypes | Number (%) | Gene (polymorphism) | R² | ΔR² | Unexplained variance (%) | p value |
|------|-----------|------------|---------------------|----|-----|-------------------------|--------|
|      |           | HD patients | Controls            |    |     |                         |        |
| TP53 | GG        | 89 (53)    | 86 (51)             | .308 | -   |                         |        |
|      | CG        | 69 (41)    | 69 (41)             |     |     |                         |        |
|      | CC        | 9 (5)      | 13 (8)              |     |     |                         |        |
| hCAD | GG        | 141 (84)   |                     | .314 | .006 | 0.9                     | .130   |
|      | AG        | 23 (14)    |                     |     |     | 0.4                     | .590   |
|      | AA        | 3 (2)      |                     |     |     |                         |        |

Authors’ contributions
LA initiated the study, carried out the molecular genetic studies and drafted the manuscript. PHK participated in the data analysis. JA and CS had ascertained the clinical status of the patients, and JTE participated in the study design, the coordination and finalized the analyses as well as the paper.

References
1. The Huntington’s Disease Collaborative Research Group: Cell 1993, 72:971-983.
2. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Yound C, Martin E, Vonsattel JP, Carraway R, Reeves SA, Boyce FM, Aronin N: Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995, 14:1075-1081.
3. Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL: Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet 1999, 36:108-111.
4. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 6810:307-310.
5. Steffen JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM: The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000, 97:6763-6768.
6. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999, 19:1092-1100.
7. Bonafe M, Salvato S, Barbi C, Trapassi C, Tocco F, Storci G, Invidia L, Vannini I, Rossi M, Marzi E, Misho M, Capri M, Olivieri F, Antonicelli R, Memo M, Uberti D, Nasimias B, Sorbi S, Monti D, Franceschi C: The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death Differ 2004, 11:962-973.
8. Chattopadhyay B, Baki K, Mukhopadhyay S, Bhattacharyya NP: Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes. Neurosci Lett 2005, 374:81-6.
9. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamata A, Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998, 6662:43-50.
10. Arning L, Kraus PH, Valentin S, Saft C, Epllen JT: NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics 2005, 6:25-8.
11. Warner JP, Barron LH, Brock DJ: A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington’s disease chromosomes. Mol Cell Probes 1993, 7:235-239.

12. Donehower LA: p53: guardian AND suppressor of longevity? Exp Gerontol 2005, 40:7-9.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/6/35/prepub